Fundraising FoxBioGeneration Ventures — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction.
BiotechDigital HealthMedical DevicesBasel, CH
Botond Roska(Researcher (M.D., Ph.D.))Bence György(IOB Assistant Professor & Head of Clinical Translation)inKatherine High(CEO)in
Co-investorsARCH Venture PartnersNovartis Venture FundF-Prime CapitalGV (Google Ventures)
Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.
BiotechDeep TechHealthtechMedical Devices
Mohit Trikha(CEO)inSophia Randolph(Chief Medical Officer)in
Co-investorsBOMGimvHealthCapM VenturesRed Tree VentureNovo Holdings
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Tanai Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.